Colorectal cancer blood test vs stool test or colonoscopy: where the new option fits

The 2026 FDA approval of prescription-use SimpleScreen CRC adds a blood-based colorectal-cancer screening option for average-risk adults age 45 and older within its labeling. A positive result should be followed by colonoscopy; the test does not replace diagnostic or surveillance colonoscopy. A negative result does not rule out colorectal cancer or advanced precancerous lesions.¹²⁵

This is a pathway decision, not a contest for the easiest sample. Screening benefit depends on using a valid test in an eligible population and completing colonoscopy when a non-colonoscopy screen is positive.⁴ FDA approval did not establish a SimpleScreen-specific repeat interval; a required postapproval study is intended to validate one.²

Product approval and guideline endorsement are different records

FDA’s PMA record shows that SimpleScreen CRC was approved on July 24, 2026.¹ The approval order defines the product-specific population, warnings, and follow-up; it does not automatically revise every professional or payer guideline on that date. The current USPSTF recommendation predates this approval and lists established strategies without this product.³

Do not call a blood test “noninvasive colonoscopy.” It detects a blood signal; it does not see the colon, remove a polyp, biopsy tissue, or explain symptoms.

Confirm the average-risk boundary

The approval is for the population in the product labeling, not everyone age 45 or older. Before ordering, the responsible clinician should review:

• current symptoms such as bleeding or unexplained changes;
• prior colorectal cancer, adenomas, or other relevant findings;
• inflammatory bowel disease;
• inherited syndromes or significant family history;
• prior colonoscopy quality, findings, and recommended interval;
• a previously positive screening test;
• age, overall health, and the ability to complete follow-up.

These facts can route a person to diagnostic or surveillance care rather than average-risk screening. A wellness service should not erase history with a checkout checkbox.

Detection differs by target

The Summary of Safety and Effectiveness Data should be read for the studied population, reference standard, evaluable samples, sensitivity, specificity, stage distribution, advanced precancerous lesion detection, and confidence intervals.⁵ A headline “cancer detection” figure does not describe detection of early-stage cancer, advanced adenomas, every lesion location, or performance outside the study population.

Sensitivity answers how often the test was positive among people with the target condition in the study. Specificity answers how often it was negative among people without the target. Positive predictive value changes with prevalence and population. None is an individual guarantee.

Ask the seller to present separate values for colorectal cancer and advanced precancerous lesions. Finding invasive cancer while missing many removable precursors is a different prevention profile from a method that directly visualizes and removes polyps.

Approval adds an option; it does not rank every strategy

PMA approval means FDA found reasonable assurance of safety and effectiveness for the product’s intended use based on the submitted evidence. It does not mean the blood test detects every important target as well as stool testing or colonoscopy, has a guideline-preferred interval, or produces better long-term outcomes than every alternative.

Compare the endpoints that matter for screening:

• colorectal-cancer sensitivity overall and by stage;
• advanced precancerous lesion sensitivity;
• specificity and expected false-positive burden;
• invalid or unevaluable specimens;
• adherence to completing the first test;
• colonoscopy completion after a positive result;
• complications and downstream care;
• evidence that the complete repeated strategy reduces illness or death.

The SSED reports product performance in the pivotal study; it cannot forecast real-world benefit if people with positive results do not reach colonoscopy.⁵ Conversely, a theoretically stronger test creates no benefit when access, preparation, time, or fear prevents completion. Choice should preserve the whole pathway.

Prescription ordering should include history reconciliation

The approval order restricts sale and distribution to prescription use.² That should mean more than a clinician’s name generated behind an online checkout. The order should include a review of symptoms, prior tests, colonoscopy and pathology, family history, high-risk conditions, and the date and quality of the last complete screen.

Ask how the result enters the clinician’s longitudinal record and whether the ordering service can see a colonoscopy performed elsewhere. Duplicate screening can create conflicting signals. A prior positive stool test should not be “double-checked” with a blood test to avoid the indicated colonoscopy.

If a specimen fails quality controls or the result is indeterminate, the program should state whether a redraw, different screening method, or clinical review occurs and who pays. An invalid result is not negative.

A positive result starts the next step

FDA’s approval materials say a positive SimpleScreen result should be followed by colonoscopy.² Before choosing the blood test, identify who will:

1. receive and communicate the result;
2. place the colonoscopy referral;
3. obtain authorization and locate an in-network facility;
4. transfer the exact lab report and risk history;
5. track completion and pathology;
6. manage a delayed, incomplete, or declined follow-up.

If the program only delivers a portal result and advises the customer to “see your doctor,” the most important part of a positive pathway is unowned.

A negative result is not a clean bill of health

No screening test has perfect sensitivity. A negative result cannot explain symptoms and does not override a diagnostic evaluation. It does not establish a SimpleScreen-specific repeat interval. Current labeling directs patients to continue guideline-recommended colorectal screening at appropriate intervals while FDA’s required postapproval study is intended to validate a testing interval.²

Avoid stacking a blood test, stool test, and consumer multi-cancer panel simply to feel “more certain.” Multiple tests can produce discordant results and false positives without a validated combined algorithm. If two tests are proposed, ask what published pathway explains how to interpret every combination.

This article is specifically about a colorectal screening product. It should not be generalized to multi-cancer early-detection tests, which measure different signals and have different authorization and follow-up questions.

Compare access as a complete cycle

Price should include the order, blood draw or kit, laboratory analysis, clinician interpretation, result communication, reminders, repeat testing, and positive follow-up. Coverage can differ across methods and plans. A consumer cash price for the first test does not forecast the cost of diagnostic colonoscopy, anesthesia, pathology, travel, or missed work.

Ask whether a positive screening colonoscopy is processed under screening or diagnostic benefits for the specific plan, without accepting a universal promise. Preserve the plan response and date.

The decisive question

Ask: “Am I in this exact test’s labeled average-risk population, what important lesions can it miss, what guideline screening plan applies while its repeat interval is being validated, and who ensures that a positive result reaches colonoscopy?” Convenience is valuable only when the full screening loop remains intact.